140
Participants
Start Date
March 30, 2015
Primary Completion Date
September 30, 2021
Study Completion Date
March 31, 2023
Ipilimumab
Given IV
Laboratory Biomarker Analysis
Correlative studies
Nivolumab
Given IV
Pharmacological Study
Correlative studies
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
National Institutes of Health Clinical Center, Bethesda
Children's Healthcare of Atlanta - Egleston, Atlanta
Children's Hospital of Alabama, Birmingham
Saint Jude Children's Research Hospital, Memphis
Cincinnati Children's Hospital Medical Center, Cincinnati
Riley Hospital for Children, Indianapolis
C S Mott Children's Hospital, Ann Arbor
Children's Hospital of Wisconsin, Milwaukee
University of Minnesota/Masonic Cancer Center, Minneapolis
Lurie Children's Hospital-Chicago, Chicago
Washington University School of Medicine, St Louis
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Children's Hospital Colorado, Aurora
Children's Hospital Los Angeles, Los Angeles
Children's Hospital of Orange County, Orange
UCSF Medical Center-Mission Bay, San Francisco
Lucile Packard Children's Hospital Stanford University, Palo Alto
Oregon Health and Science University, Portland
Seattle Children's Hospital, Seattle
Dana-Farber Cancer Institute, Boston
Hospital for Sick Children, Toronto
National Cancer Institute (NCI)
NIH